The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000627358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/05/2026
Date registered
Help: Date registered
22/05/2026
Date last updated
Help: Date last updated
22/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Adjunctive Fludrocortisone with transcriptome evaluation in critically ill adults with septic shock- FLUDRO-SHOCK Trial
Scientific title
A harmonised Phase 3 multi-centre, adaptive, randomised, blinded, placebo-controlled trial of adjunctive fludrocortisone (50 mcg or 100 mcg) in critically ill patients with septic shock receiving hydrocortisone, evaluating survival and functional recovery and the influence of immunological and transcriptomic profiles on treatment response.
Additional trial identifiers [1] 317201 0
Protocol Number: TGI 358376-74625
Universal Trial Number (UTN)
Trial acronym
FLUDRO-SHOCK- Adjunctive FLUDrocortisone with tRanscriptOme evaluation in septic SHOCK
Related trial records

Health condition
Health condition(s) studied:
Septic shock 341782 0
Condition category
Condition code
Inflammatory and Immune System 337863 337863 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants receiving intravenous hydrocortisone at a daily dose of 200 mg/day as adjunctive treatment for septic shock and eligible for FLUDRO-SHOCK study, will be randomised to receive either:
1. 50 mcg of oral or enteral fludrocortisone daily, or
2. 100 mcg of oral or enteral fludrocortisone daily, or
3. Matching oral or enteral placebo daily
For seven days or until discharge from intensive care unit (ICU).
The study drug will be administered to patients in the ICU by delegated site team staff members. To assess adherence to the intervention, monitors will verify that the study drug administration documented in source records (electronic medical records – eMRs) is consistent with the data recorded in the study database.
Intervention code [1] 333969 0
Treatment: Drugs
Description of the comparator or control
Matching oral or enteral placebo, for seven days or until discharge from ICU. The excipients for placebo tablets will be Lactose monohydrate, Sodium Starch Glycolate and Magnesium Stearate.
Control group
Placebo

Outcomes
Primary outcome [1] 345322 0
Days alive and free of organ support (DAFOS) to 28 days after randomisation
Timepoint [1] 345322 0
28 days after randomisation
Secondary outcome [1] 461290 0
1. Mortality at 28 days, 90 days, 6 months and 12 months
Timepoint [1] 461290 0
28 days, 90 days, 6 months and 12 months post-randomisation
Secondary outcome [2] 461598 0
2. Days alive and free of organ support (DAFOS) until day 90
Timepoint [2] 461598 0
Up to 90 days post-randomisation
Secondary outcome [3] 461601 0
3. Proportion of patients treated with new onset renal replacement therapy until 90 days
Timepoint [3] 461601 0
Up to 90 days post-randomisation
Secondary outcome [4] 461603 0
4. Days alive and free of mechanical ventilatory support until 90 days
Timepoint [4] 461603 0
Up to 90 days post-randomisation
Secondary outcome [5] 461606 0
5. Days alive and out of ICU and out of hospital censored at 90 days
Timepoint [5] 461606 0
Up to 90 days post-randomisation
Secondary outcome [6] 461607 0
6. Number of readmissions to hospital, censored at 90 days
Timepoint [6] 461607 0
Up to 90 days post-randomisation
Secondary outcome [7] 461608 0
7. Number of new onset infections in index hospital admission (defined by treatment with new antibiotics 48 hours after randomisation to index hospital discharge). Commencement of antibiotics for peri-operative prophylaxis will be excluded
Timepoint [7] 461608 0
From 48 hours post-randomisation to hospital discharge
Secondary outcome [8] 461609 0
8. New onset bacteraemia (more than 2 days after randomisation and up to index hospital discharge). Bacteraemia with skin commensals will be excluded
Timepoint [8] 461609 0
From 2 days post-randomisation to hospital discharge
Secondary outcome [9] 461610 0
Long-term outcome 1: Quality of life at 90 days, 6 months and 12 months
Timepoint [9] 461610 0
90 days, 6 months and 12 months post-randomisation
Secondary outcome [10] 461611 0
Long-term outcome 2: Health economic analysis at 12 months
Timepoint [10] 461611 0
12 months post-randomisation

Eligibility
Key inclusion criteria
Critically ill adult patients aged 18 years or older meeting Sepsis-3 criteria for septic shock and receiving high-level respiratory and cardiovascular support will be eligible if they meet all of the following inclusion criteria and no exclusion criteria:
1. Shock presumed due to infection
2. Treatment with a vasopressor infusion to maintain a systolic blood pressure greater than 90 mmHg or a mean arterial pressure greater than or equal to 65 mmHg, after receiving adequate fluid resuscitation (in the opinion of the treating clinician)
3. Plasma lactate concentration greater than 2.0 mmol/L
4. Being treated with intravenous hydrocortisone at a daily dose of 200 mg per day as adjunctive treatment for septic shock
5. Use of one of the following:
a) Invasive mechanical ventilation, or
b) Non-invasive ventilation (CPAP or BiPAP), or
c) Oxygen supplementation with an oxygen flow greater than 10 L/min independent of the delivery system and a fraction of inspired oxygen of 0.5 or above, or
d) Veno-venous extracorporeal membrane oxygenation
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria:
1. Met all inclusion criteria for more than 12 hours
2. Death is deemed imminent or inevitable by treating ICU specialist
3. Patients with documented systemic fungal infection at the time of randomisation
4. Patients with documented allergy to fludrocortisone
5. Patients unable to receive enteral medications
6. An underlying disease process with a life expectancy of less than 28 days
7. Pregnancy (confirmed or suspected)
8. Receiving hydrocortisone or fludrocortisone for conditions other than septic shock
9. Prior enrolment in this trial
10. Known or documented objections to research participation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation will occur via a secure web-based portal.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated block randomisation sequence stratified by site.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,WA,VIC
Recruitment outside Australia
Country [1] 28081 0
New Zealand
State/province [1] 28081 0
Country [2] 28082 0
India
State/province [2] 28082 0
Country [3] 28083 0
Canada
State/province [3] 28083 0
Country [4] 28084 0
United Kingdom
State/province [4] 28084 0

Funding & Sponsors
Funding source category [1] 321780 0
Government body
Name [1] 321780 0
National Health and Medical Research Council (NHMRC)
Country [1] 321780 0
Australia
Funding source category [2] 321782 0
Government body
Name [2] 321782 0
Medical Research Future Fund (MRFF)
Country [2] 321782 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
The George Institute for Global Health
Address
Country
Australia
Secondary sponsor category [1] 324625 0
None
Name [1] 324625 0
Address [1] 324625 0
Country [1] 324625 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320325 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 320325 0
Ethics committee country [1] 320325 0
Australia
Date submitted for ethics approval [1] 320325 0
26/09/2025
Approval date [1] 320325 0
26/11/2025
Ethics approval number [1] 320325 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150094 0
A/Prof Naomi Hammond
Address 150094 0
The George Institute for Global Health L8, Health Translation Hub, 55 Botany Street Randwick NSW 2031
Country 150094 0
Australia
Phone 150094 0
+61 02 8052 4352
Fax 150094 0
Email 150094 0
Contact person for public queries
Name 150095 0
Naomi Hammond
Address 150095 0
The George Institute for Global Health L8, Health Translation Hub, 55 Botany Street Randwick NSW 2031
Country 150095 0
Australia
Phone 150095 0
+61 02 8052 4352
Fax 150095 0
Email 150095 0
Contact person for scientific queries
Name 150096 0
Prof Balasubramanian Venkatesh
Address 150096 0
The George Institute for Global Health; L8, Health Translation Hub, 55 Botany Street Randwick NSW 2031
Country 150096 0
Australia
Phone 150096 0
+61 2 8052 4460
Fax 150096 0
Email 150096 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.